Week 8 - L6 - Non-Covalent Interactions, Binding Sites, and Allosteric Modulation in Proteins
Structural Analysis of Protein-Ligand Complexes
Role of Non-Covalent Interactions: Non-covalent interactions facilitate the binding of proteins to various target molecules, including other proteins, nucleic acids, and small molecules.
Significance of High-Resolution Structures: High-resolution crystal structures of proteins bound to ligands or drugs provide critical molecular insights:
Ligand Binding Site Identification: Precisely locates where a drug or ligand binds on the target protein.
Conformational Changes: Visualizes structural shifts and dynamic responses of the protein induced by ligand binding.
Inventory of Stabilizing Interactions: Enables the complete mapping of non-covalent interactions stabilizing the complex, including:
Van der Waals contacts
Hydrogen bonds
Ion pairs
Hydrophobic interactions
Structure-Based Rational Drug Design:
Structural analysis guides chemical modification of drug candidates to enhance binding affinity and specificity.
Functional Group Addition: Adding groups (such as a hydroxyl group) can introduce additional hydrogen bonds to strengthen binding.
Group Removal: Identifying and removing unfavorable structural moieties improves overall binding efficiency.
Newly designed drug candidates are synthesized and empirically tested.
Mapping Mutations: High-resolution complex structures allow mapping of genetic mutations directly onto the ligand binding pocket to evaluate how specific amino acid substitutions interfere with ligand binding or enzymatic catalysis.
Features and Mechanisms of Binding Sites
Pocket Plasticity and Flexibility:
Binding pockets on proteins can be dynamic and plastic.
Pockets can expand or contract to accommodate ligands of different sizes.
Pocket Lids:
Certain binding pockets possess structural lids that close over a bound ligand.
Function: Prevents the premature release of reaction intermediates, allowing an enzyme to completely finish a chemical reaction.
Release: The lid opens to release the final reaction product only after the reaction is fully complete.
Venus Flytrap Mechanism:
Proteins utilizing this mechanism possess a cleft situated between structural domains where the ligand binds.
Upon ligand binding, the domains snap shut around the ligand, trapping it inside.
Enzymatic Role: Traps substrate molecules inside to ensure reaction completion prior to reopening and product release.
Receptor Role: Structural closure around a signal molecule alters overall receptor shape, transducing a signal across the cell to indicate the presence of the signaling molecule.
Interface Binding Sites and Molecular Glues:
Binding sites can be located directly at the interface between two distinct protein molecules.
Example: Adenosine triphosphate () can act as a molecular glue, holding two protein molecules bound to one another.
Regulation and Inhibitor Mechanisms in Metabolic Pathways
Feedback Inhibition in Metabolism:
Enzymatic activity in metabolic pathways is regulated through feedback inhibition to control levels of metabolism.
Isoleucine Biosynthetic Pathway: In the Leninger pathway, threonine is converted into isoleucine through a multi-step sequence catalyzed by distinct enzymes.
Mechanism: Accumulation of excess isoleucine leads to the inhibition of an early pathway enzyme, threonine dehydrotase (threonine dehydratase), halting the synthesis pathway and preventing overproduction of isoleucine.
Direct vs. Allosteric Inhibition in Drug Action:
Direct (Competitive) Inhibition:
The inhibitor binds directly to the primary active site pocket, competing with the natural substrate.
The inhibitor possesses a higher binding affinity than the substrate, outcompeting it.
Occupancy of the active site by the inhibitor prevents substrate binding and catalytic conversion.
Example: Lipitor functions as a direct competitive inhibitor of an enzyme in the cholesterol biosynthesis pathway to lower blood cholesterol levels.
Allosteric Inhibition:
The inhibitor does not bind to the primary active site and does not compete directly with the natural substrate.
The inhibitor binds to a secondary, physically distinct site termed the allosteric site.
Binding induces a conformational change propagated to the active site, reducing catalytic efficiency or completely preventing the reaction.
Example: Isoleucine acts as an allosteric inhibitor of threonine dehydrotase.
Allosteric Modulators and Structural Dynamics
Properties of Allosteric Modulators:
Allosteric modulators bind to allosteric sites located either on the same polypeptide chain or on distinct subunits of oligomeric proteins.
Modulators induce conformational changes that modify protein activity or affinity at the primary ligand-binding site.
Modulators can modulate enzymatic activity or alter receptor responses to external stimuli.
Types of Allosteric Modulators:
Negative Allosteric Modulators: Decrease enzymatic activity or ligand binding affinity.
Positive Allosteric Modulators: Enhance catalytic activity, increase binding affinity, or promote enzymatic reactions.
Structural Mechanism of Positive Allosteric Modulation:
Subunit Organization: In dimeric enzymes (such as heterodimers formed by two distinct polypeptide chains encoded by separate genes), functions are split between a catalytic subunit (containing the active site) and a regulatory subunit (containing the allosteric site).
Unbound State (Suboptimal Geometry):
In the absence of a positive modulator, the catalytic site exhibits a suboptimal geometry.
Substrates are unable to bind, or catalytic residues within the active site are misaligned, rendering the enzyme inactive.
Bound State (Enhanced Geometry):
Binding of a positive allosteric modulator to the regulatory subunit triggers structural realignments across both regulatory and catalytic subunits.
Conformational changes alter the active site pocket geometry to fit the substrate perfectly.
Catalytic residues become aligned to carry out the chemical reaction efficiently.
Allosteric Modulation Case Study: Ivacaftor (Avacaftor) and CFTR:
Target: Cystic Fibrosis Transmembrane Conductance Regulator (), a chloride ion channel featuring a central pore.
Binding Site: The drug Ivacaftor (Avacaftor) binds to an allosteric site located on the outer periphery of the mutant receptor, far removed from the central ion channel pore.
Mechanism: Despite binding on the peripheral exterior of the protein, Ivacaftor induces conformational changes that modulate and enhance chloride ion conduction through the central channel, serving as a functional positive allosteric modulator.